Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited to acquire its Wellness Portfolio, in a transaction that could have a total consideration of up to ₹46.7 crore.
According to the company’s regulatory disclosure dated September 23, 2026, the acquisition will be undertaken on a going-concern basis through a slump sale. Jagsonpal said the move is aimed at strengthening its pharmaceutical portfolio, expanding its presence across relevant therapeutic segments and increasing its market reach.
The transaction includes an initial consideration of ₹23.7 crore payable at closing. An additional consideration of up to ₹23 crore will be linked to sales achieved during FY 2027-28, taking the total consideration to a maximum of ₹46.7 crore.
The Wellness Portfolio generated a turnover of ₹24.6 crore in FY 2025-26, according to the disclosure. The company stated that the transaction does not fall under related-party transactions and that none of the promoter, promoter group or group companies has an interest in the portfolio or seller.
Jagsonpal expects the acquisition to be completed on or before November 1, 2026, subject to fulfilment of the conditions precedent and other terms of the BTA. The company has stated that no governmental or regulatory approvals are required for the acquisition.
The acquired business has a presence in India and includes identified products, assets, contracts, employees and other arrangements associated with the Wellness Portfolio.
In its accompanying announcement, Jagsonpal said the acquisition will bring an established product portfolio and existing market presence. The company plans to integrate the business with its existing commercial platform and use its distribution network to create operating synergies.
Jagsonpal Managing Director Manish Gupta said the acquisition will expand the company's presence across complementary therapeutic segments, particularly women's healthcare, while following its focused and asset-light growth approach.
The company also said the transaction is expected to provide opportunities for expanding its field force, strengthening pan-India presence and cross-selling products across its portfolio.
